After concluding a phase 3 study of its COVID-19 vaccine candidate, Pfizer revealed Wednesday that the vaccine has 95% efficiency.
Here & Now‘s Robin Young gets the latest from Helen Branswell, senior writer at STAT, the health and medicine publication.
This article was originally published on WBUR.org.
Copyright 2020 NPR. To see more, visit https://www.npr.org. 9(MDA5MTc0MDI0MDEzMzE4MjI4ODdlOTk4MA004))